809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival

Trisha M Wise‐Draper ,Muhammad Kashif Riaz,Alice Tang,Chad Zender,Jonathan Mark,Keith Casper,Matthew Old,J Jack Lee,John M Kaczmar ,Ann M Gillenwater ,Aubrey Hamilton,Michelle Mierzwa,Shuchi Gulati,Diana Bell,Sheena M Lanverman ,Yash Patil,Layne Weatherford,Neal E Dunlap ,Roman Jandarov,Benjamin H Hinrichs ,Sarah Palackdharry,Francis P Worden ,Mario Medvedovich,Vinita Takiar,Maura L Gillison

doi:10.1136/jitc-2020-sitc2020.0809

809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival

Trisha M Wise‐Draper , Muhammad Kashif Riaz + Show 23 more

Open Access

https://doi.org/10.1136/jitc-2020-sitc2020.0809

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Nov 1, 2020
Citations: 1	License type: CC BY-NC 4.0

Affiliation: University of Charleston, University of Cincinnati, The University of Texas MD Anderson Cancer Center, University of Michigan–Ann Arbor, University of Louisville, Eastern Virginia Medical School, The Ohio State University

#Head And Neck Squamous Cell Carcinoma #Intermediate-risk Features + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundPatients with newly diagnosed, resected, head and neck squamous cell carcinoma (HNSCC) with high-risk (positive margins, extracapsular spread [ECE]) or intermediate-risk pathological features have an estimated 1-year disease free survival...

Full Text